Mumbai, 28 January (IANS). Consolidated profits of the country’s veteran pharma company Cipla increased by 49 percent to Rs 1,574.6 crore on an annual basis in the third quarter of FY 25, which was Rs 1,068.5 crore in the same quarter of the previous financial year.
The company said in the exchange filing that the income from the company’s operations has increased by 7 percent to Rs 7,073 crore on an annual basis, which was Rs 6,604 crore in the third quarter of FY 24.
However, the company’s income has been flat on a quarterly basis and the company’s income in the second quarter of FY 25 was Rs 7,051 crore.
The company’s income from Indian business has increased by 10 percent to Rs 3,146 crore compared to the same quarter last year. At the same time, its branded prescription business has performed better than market growth in major treatments.
Cipla’s Ebita has increased by 15.7 percent to Rs 1,989 crore on an annual basis in the December quarter. The EBITa margin 184 base points have increased to 28.1 percent.
In the December quarter, Cipla’s expenditure increased by 5 percent to Rs 5,378 crore as compared to the previous year, although it declined by 1.3 percent on a quarterly basis.
Cipla’s New Venture Segment also performed well, which earned an income of Rs 341 crore in the third quarter of FY 2025, which income of the same period of FY 2024 and income of Rs 281 crore and income for the previous quarter is more than Rs 320 crore. Is.
According to its filing, the company’s growth was inspired by strong performance in emerging markets and Europe.
Cipla’s stock rose 2.21 percent to close at 1,427 on Tuesday.
— IANS
ABS/
